Literature DB >> 23625938

Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.

Daniel J Wolter1, Julia C Emerson, Sharon McNamara, Anne M Buccat, Xuan Qin, Elizabeth Cochrane, Laura S Houston, Geraint B Rogers, Peter Marsh, Karandeep Prehar, Christopher E Pope, Marcella Blackledge, Eric Déziel, Kenneth D Bruce, Bonnie W Ramsey, Ronald L Gibson, Jane L Burns, Lucas R Hoffman.   

Abstract

BACKGROUND: Cystic fibrosis (CF) lung disease is associated with diverse bacteria chronically infecting the airways. Slow-growing, antibiotic-resistant mutants of Staphylococcus aureus known as small-colony variants (SCVs) have been isolated from respiratory secretions from European adults and children with CF lung disease using specific but infrequently used culture techniques. Staphylococcus aureus SCVs can be selected either by exposure to specific antibiotics or by growth with another CF pathogen, Pseudomonas aeruginosa. We sought to determine the prevalence, clinical significance, and likely mechanisms of selection of S. aureus SCVs among a US cohort of children with CF.
METHODS: We performed a 2-year study of 100 children with CF using culture techniques sensitive for S. aureus SCVs, and evaluated associations with clinical characteristics using multivariable regression models.
RESULTS: Staphylococcus aureus SCV infection was detected among 24% of participants and was significantly associated with a greater drop in lung function during the study (P = .007, adjusted for age and lung function at enrollment). This association persisted after adjusting for infection with other known CF pathogens, including P. aeruginosa and methicillin-resistant S. aureus. Evidence indicated that S. aureus SCVs were likely selected in vivo by treatment with the antibiotic trimethoprim-sulfamethoxazole and possibly by coinfection with P. aeruginosa.
CONCLUSIONS: Infection with SCV S. aureus was independently associated with worse CF respiratory outcomes in this pediatric cohort. As many clinical microbiology laboratories do not specifically detect S. aureus SCVs, validation and extension of these findings would require widespread changes in the usual laboratory and clinical approaches to these bacteria.

Entities:  

Keywords:  Staphylococcus aureus; children; cystic fibrosis; lung function; small-colony variant

Mesh:

Substances:

Year:  2013        PMID: 23625938      PMCID: PMC3888146          DOI: 10.1093/cid/cit270

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

Review 1.  Prophylactic antibiotics in cystic fibrosis: a conviction without evidence?

Authors:  Alan Smyth
Journal:  Pediatr Pulmonol       Date:  2005-12

Review 2.  Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections.

Authors:  Richard A Proctor; Christof von Eiff; Barbara C Kahl; Karsten Becker; Peter McNamara; Mathias Herrmann; Georg Peters
Journal:  Nat Rev Microbiol       Date:  2006-04       Impact factor: 60.633

3.  Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis.

Authors:  M Rosenfeld; J Emerson; F Accurso; D Armstrong; R Castile; K Grimwood; P Hiatt; K McCoy; S McNamara; B Ramsey; J Wagener
Journal:  Pediatr Pulmonol       Date:  1999-11

4.  Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis.

Authors:  B Kahl; M Herrmann; A S Everding; H G Koch; K Becker; E Harms; R A Proctor; G Peters
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

Review 5.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

6.  Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Authors:  Jeffrey S Wagener; Lawrence Rasouliyan; Donald R VanDevanter; David J Pasta; Warren E Regelmann; Wayne J Morgan; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2012-08-08

7.  Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

Authors:  Tim W R Lee; Keith G Brownlee; Steven P Conway; Miles Denton; James M Littlewood
Journal:  J Cyst Fibros       Date:  2003-03       Impact factor: 5.482

8.  Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis.

Authors:  P H Gilligan; P A Gage; D F Welch; M J Muszynski; K R Wait
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

9.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08

10.  Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study.

Authors:  Barbara C Kahl; Angelika Duebbers; Gabriele Lubritz; Johannes Haeberle; Hans G Koch; Barbara Ritzerfeld; Marion Reilly; Erik Harms; Richard A Proctor; Mathias Herrmann; Georg Peters
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

View more
  66 in total

1.  Response to "In vivo attenuation and genetic evolution of a ST247-SCCmecI MRSA clone after 13 years of pathogenic bronchopulmonary colonization in a patient with cystic fibrosis: implications of the innate immune response".

Authors:  A Kriegeskorte; D Block; B C Kahl
Journal:  Mucosal Immunol       Date:  2015-02-18       Impact factor: 7.313

2.  Prevention of Staphylococcus aureus Ventilator-Associated Pneumonia: Conventional Antibiotics Won't Cut It.

Authors:  Jason P Burnham; Marin H Kollef
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

3.  Pseudomonas aeruginosa PA14 Enhances the Efficacy of Norfloxacin against Staphylococcus aureus Newman Biofilms.

Authors:  Giulia Orazi; Fabrice Jean-Pierre; George A O'Toole
Journal:  J Bacteriol       Date:  2020-08-25       Impact factor: 3.490

Review 4.  Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.

Authors:  Barbara C Kahl; Karsten Becker; Bettina Löffler
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

5.  [Persistent and recurrent skin and soft tissue infections by Staphylococcus aureus. Impact of the small colony-variant (SCV) phenotype and of Panton-Valentine leukocidin (PVL)-positive S. aureus isolates].

Authors:  K Becker; A Kriegeskorte; C Sunderkötter; B Löffler; C von Eiff
Journal:  Hautarzt       Date:  2014-01       Impact factor: 0.751

6.  Understanding the Role of Staphylococcus aureus in Non-Cystic Fibrosis Bronchiectasis: Where Are We Now?

Authors:  Ranjani Somayaji; Kathleen J Ramos; Lucas R Hoffman
Journal:  Ann Am Thorac Soc       Date:  2018-03

7.  Small Colony Variants of Pseudomonas aeruginosa Display Heterogeneity in Inhibiting Aspergillus fumigatus Biofilm.

Authors:  Rajesh Anand; Richard B Moss; Gabriele Sass; Niaz Banaei; Karl V Clemons; Marife Martinez; David A Stevens
Journal:  Mycopathologia       Date:  2017-08-07       Impact factor: 2.574

Review 8.  How can the cystic fibrosis respiratory microbiome influence our clinical decision-making?

Authors:  Geraint B Rogers; Kenneth D Bruce; Lucas R Hoffman
Journal:  Curr Opin Pulm Med       Date:  2017-11       Impact factor: 3.155

9.  Optimized In Vitro Antibiotic Susceptibility Testing Method for Small-Colony Variant Staphylococcus aureus.

Authors:  Mimi R Precit; Daniel J Wolter; Adam Griffith; Julia Emerson; Jane L Burns; Lucas R Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

10.  Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model.

Authors:  Laura M Filkins; Jyoti A Graber; Daniel G Olson; Emily L Dolben; Lee R Lynd; Sabin Bhuju; George A O'Toole
Journal:  J Bacteriol       Date:  2015-04-27       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.